Indivior Pharmaceuticals Inc (INDV)
Automate Your Wheel Strategy on INDV
With Tiblio's Option Bot, you can configure your own wheel strategy including INDV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INDV
- Rev/Share 9.448
- Book/Share -1.656
- PB -21.407
- Debt/Equity -1.7198
- CurrentRatio 0.9554
- ROIC 0.3933
- MktCap 4423096500.0
- FreeCF/Share 1.0759
- PFCF 32.8884
- PE 26.6943
- Debt/Assets 0.2514
- DivYield 0
- ROE -0.6042
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 3
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INDV | H.C. Wainwright | -- | Buy | -- | $27 | Aug. 6, 2025 |
| Resumed | INDV | Jefferies | -- | Buy | -- | $20 | July 22, 2025 |
| Initiation | INDV | Rodman & Renshaw | -- | Buy | -- | $16 | Jan. 28, 2025 |
News
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Neutral
Zacks highlights how Indivior, FIGS and Ulta Beauty delivered outsized gains as its ranks, recommendations and focus lists beat a volatile market.
Read More
4 Stocks Trading Near 52-Week High With Room to Rise Further
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors target stocks that have been on a bullish run. Stocks like INDV, AUGO, ERO and OI are seeing price strength, and the momentum is likely to continue.
Read More
Indivior Announces Inclusion in the S&P SmallCap 600® Index
Published: December 22, 2025 by: PRNewsWire
Sentiment: Neutral
RICHMOND, Va. , Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P SmallCap 600® index, effective today.
Read More
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
Published: December 17, 2025 by: PRNewsWire
Sentiment: Neutral
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified. Post-hoc analyses indicated the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants reporting high-frequency fentanyl use.
Read More
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
Published: November 19, 2025 by: PRNewsWire
Sentiment: Neutral
RICHMOND, Va. , Nov. 19, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference: Piper Sandler 37th Annual Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Tuesday, December 2 nd.
Read More
4 Must-Buy Efficient Stocks to Enrich Your Portfolio in 2025
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
INDV, PRLB, LVS and OII top Zacks' efficiency screen with strong margins and solid earnings surprises.
Read More
Indivior PLC (INDV) Q3 2025 Earnings Call Transcript
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Indivior PLC ( INDV ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Jason Thompson - Vice President of Investor Relations Joseph Ciaffoni - CEO & Director Patrick Barry - Chief Commercial Officer Ryan Preblick - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Christian Glennie - Stifel, Nicolaus & Company, Incorporated, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Thibault Boutherin - Morgan Stanley, Research Division Presentation Operator Good day, and thank you for standing by.
Read More
Indivior PLC (INDV) Beats Q3 Earnings and Revenue Estimates
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Indivior PLC (INDV) came out with quarterly earnings of $0.72 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.54 per share a year ago.
Read More
Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Indivior PLC (NASDAQ:INDV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Joseph Ciaffoni - CEO & Director Ryan Preblick - Chief Financial Officer Conference Call Participants Thibault Boutherin - Morgan Stanley, Research Division Presentation Thibault Boutherin Equity Analyst I think we start. Good morning, everyone.
Read More
Indivior to Participate in Upcoming Investor Events
Published: August 20, 2025 by: PRNewsWire
Sentiment: Neutral
RICHMOND, Va. , Aug. 20, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the following investor events: Morgan Stanley 23rd Annual Global Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Monday, September 8 th.
Read More
All You Need to Know About Indivior (INDV) Rating Upgrade to Strong Buy
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Indivior (INDV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Best Momentum Stock to Buy for August 5th
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
FFIV, INDV and NVT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 5, 2025.
Read More
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
Published: June 19, 2025 by: PRNewsWire
Sentiment: Neutral
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy fentanyl use1 Additional Indivior-funded research identified OUD treatment barriers in American Indian/Alaska Native (AI/AN) people who are often affected by higher drug overdose death rates compared to other racial and ethnic groups2-5 RICHMOND, Va. , June 19, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented new findings this week at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting.
Read More
Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Indivior PLC (NASDAQ:INDV ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Ryan Preblick - CFO Conference Call Participants Carl Burns - Northland Capital Markets David Amsellem - Piper Sandler Christian Glennie - Stifel Chase Knickerbocker - Craig-Hallum Thibault Boutherin - Morgan Stanley Paul Cuddon - Deutsche Numis Operator Good day and thank you for standing by. Welcome to the Indivior PLC Q1 2025 Financial Results Conference Call.
Read More
Indivior PLC (INDV) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Indivior PLC (INDV) Q4 2024 Earnings Call Transcript
Read More
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat
Published: February 20, 2025 by: Benzinga
Sentiment: Negative
Indivior Plc INDV stock plunged following the company's fiscal year 2025 guidance that fell short of Street expectations.
Read More
About Indivior Pharmaceuticals Inc (INDV)
- IPO Date 2014-12-29
- Website https://www.indivior.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Joseph J. Ciaffoni
- Employees 1030